Alvotech stock draws Barclays upgrade ahead of FDA decisions

Alvotech stock is backed by a Barclays upgrade that raised the price target from USD 4.00 to USD 8.00 on September 16, 2026, according to Investing.com. The rating change puts regulatory milestones ahead of the company as the main valuation test.

FDA decisions set the timetable

Three proposed biosimilars tied to Simponi, Simponi Aria, Eylea and Prolia/Xgeva have FDA review completion dates aligned with December 4, 2026, Investing.com reports. The company also received FDA acceptance for review of AVT80, a proposed biosimilar to Entyvio in subcutaneous presentations, in an announcement dated August 31, 2026, according to Alvotech.

Revenue guidance meets execution risk

Alvotech reported USD 212.0 million of total revenue for the first half of 2026, compared with USD 306.0 million in the first half of 2025, a decline of 30.72 percent, according to Yahoo Finance. Management reaffirmed fiscal 2026 revenue guidance of USD 650.0 million-USD 700.0 million and adjusted EBITDA guidance of USD 180.0 million-USD 220.0 million.

The second-quarter comparison was more mixed: revenue reached USD 106.0 million against a USD 103.0 million estimate, while the adjusted loss was USD 0.054 per share versus a consensus loss of USD 0.0368 per share, MarketBeat reported on September 18, 2026.

Market value and next checkpoint

Alvotech had a market capitalization of USD 2.0 billion as of September 29, 2026. Its 52-week range was USD 2.94 to USD 9.05 on the same date, leaving regulatory execution and milestone revenue central to the investment case.

The next earnings date listed for Alvotech is November 11, 2026, according to Yahoo Finance. That date follows the December FDA decisions highlighted in the Barclays analysis.